Figure 1: Regenerative medicine in ischemic heart disease. Advantages and limitations of CD34+ and iPSCs cell-based therapies in the treatments of myocardial infarctions. HSCs indicates hematopoietic stem cells; OCs, osteogenic cells; EPCS, endothelial progenitor cells; CPCs, cardiac progenitor cells; iPSCs, induced pluripotent stem cells; CMs, cardiomyocytes; MI, myocardial infarction